Basic Science Clinical

Vascular Headache Epilepsy Immunology Movement Neuromuscular Dementia Other Topics Neurosurgery

Dystonia

What Do You Need to Know?

Definition: sustained or intermittent muscle contractions causing abnormal, often repetitive movements and/or postures; may be patterned or twisting
Sensory trick (geste antagoniste): light touch to affected area reduces dystonic posture — highly specific for dystonia
DYT-TOR1A (DYT1): most common inherited childhood-onset generalized dystonia; Ashkenazi Jewish; GAG deletion in TOR1A gene
Cervical dystonia: most common focal dystonia in adults; botulinum toxin is first-line treatment
Dopa-responsive dystonia (DYT-GCH1/Segawa disease): diurnal fluctuation, dramatic sustained levodopa response — trial levodopa in ALL young-onset dystonia
Treatment: botulinum toxin (focal), trihexyphenidyl (generalized, especially children), GPi DBS (refractory generalized/DYT-TOR1A)

Classification

Dystonia is classified along two axes per the 2013 international consensus update:

Axis 1: Clinical Characteristics

Age at Onset

Infancy: birth–2 years
Childhood: 3–12 years
Adolescence: 13–20 years
Early adulthood: 21–40 years
Late adulthood: >40 years
Earlier onset → greater tendency to generalize; later onset → more likely to remain focal

Body Distribution

Distribution	Definition	Examples
Focal	Single body region	Cervical dystonia, blepharospasm, writer’s cramp, spasmodic dysphonia
Segmental	≥2 contiguous body regions	Cranial + cervical (Meige syndrome + torticollis)
Multifocal	≥2 non-contiguous body regions	Arm + leg on opposite sides
Generalized	Trunk + ≥2 other regions	DYT-TOR1A with limb + trunk involvement
Hemidystonia	Ipsilateral arm + leg	Contralateral basal ganglia lesion (stroke, tumor)

Temporal Pattern

Persistent: present throughout the day
Action-specific: only during specific tasks (e.g., writer’s cramp)
Diurnal fluctuation: worsens as day progresses (classic for dopa-responsive dystonia)
Paroxysmal: sudden episodes of dystonia (paroxysmal kinesigenic and non-kinesigenic dystonias)

Associated Features

Isolated dystonia: dystonia is the only motor feature (with or without tremor)
Combined dystonia: dystonia + another movement disorder (myoclonus, parkinsonism)

Axis 2: Etiology

Inherited: autosomal dominant (DYT-TOR1A, DYT-THAP1, DYT-GCH1), autosomal recessive, X-linked, mitochondrial
Acquired: perinatal brain injury/CP, infection, drugs (tardive), toxins, vascular, neoplastic, brain injury
Idiopathic: sporadic or familial, no identified cause

💎 Board Pearl

Hemidystonia in an adult = structural contralateral basal ganglia lesion until proven otherwise — always image (stroke, tumor, AVM). In a child, consider delayed-onset dystonia after perinatal basal ganglia injury.
Earlier onset predicts more severe, widespread disease; focal adult-onset dystonia rarely generalizes.

Genetic Dystonias

Gene/Locus	Inheritance	Onset	Distribution	Key Features
DYT-TOR1A (DYT1)	AD (30% penetrance)	Childhood (mean ~12 yr)	Generalized (starts in limb)	GAG deletion in TOR1A; Ashkenazi Jewish (1:3,000–9,000); begins in leg/arm → generalizes; spares cranial muscles; best DBS responder
DYT-THAP1 (DYT6)	AD	Adolescence/young adult	Cranio-cervical, segmental	Prominent cranial and cervical involvement; laryngeal dystonia common; less likely to generalize than DYT1
DYT-KMT2B	AD (often de novo)	Childhood	Generalized	Childhood-onset generalized dystonia; frequently associated with intellectual disability, short stature, microcephaly; good DBS response
DYT-SGCE (DYT11)	AD (maternal imprinting)	Childhood/adolescence	Myoclonus-dystonia	Myoclonus (lightning jerks) + dystonia; alcohol-responsive; psychiatric comorbidities (OCD, anxiety); epsilon-sarcoglycan gene; maternal imprinting → disease only when inherited from father
DYT-GCH1 (DYT5a)	AD	Childhood (mean ~6 yr)	Starts in leg → generalized	Dopa-responsive dystonia (Segawa disease); diurnal fluctuation; dramatic sustained response to low-dose levodopa; GTP cyclohydrolase 1 deficiency; normal DaTSCAN
DYT/PARK-TH (DYT5b)	AR	Infancy/childhood	Generalized	Tyrosine hydroxylase deficiency; more severe than DYT-GCH1; encephalopathy, parkinsonism; partial levodopa response
DYT-ANO3 (DYT24)	AD	Adult	Cranio-cervical	Tremor-dominant dystonia; may mimic essential tremor; ANO3 (anoctamin-3) gene

💎 Board Pearl

DYT-TOR1A: test any Ashkenazi Jewish child with limb-onset dystonia; GAG deletion is a 3-bp in-frame deletion; 30% penetrance means many carriers are unaffected.
DYT-SGCE (myoclonus-dystonia): maternal imprinting = only symptomatic when inherited from father. Alcohol responsiveness is characteristic but not an indication for alcohol use.

Dopa-Responsive Dystonia

DYT-GCH1 (Segawa Disease)

Gene: GCH1 (GTP cyclohydrolase 1) — rate-limiting enzyme in tetrahydrobiopterin (BH4) synthesis
Inheritance: autosomal dominant with reduced penetrance; females affected more than males (2.5:1)
Pathophysiology: BH4 deficiency → decreased tyrosine hydroxylase activity → reduced dopamine synthesis in nigrostriatal pathway; neurons are structurally intact
Onset: childhood (mean ~6 years); typically begins with foot dystonia causing gait difficulty
Distribution: starts in lower limbs → may generalize; can be mistaken for cerebral palsy

Key Clinical Features

Diurnal fluctuation: symptoms worsen as the day progresses and improve after sleep — hallmark feature
May present with dystonia, parkinsonism, or both
Hyperreflexia and mild spasticity may be present (mimics diplegic CP)
Cognition is normal
DaTSCAN: normal (intact presynaptic dopamine terminals) — distinguishes from juvenile-onset PD (abnormal DaTSCAN)
CSF: low homovanillic acid (HVA) and biopterin; normal neopterin (distinguishes from other BH4 deficiency causes)

Treatment

Dramatic, sustained response to LOW-dose levodopa (50–200 mg/day of levodopa) — often described as “miraculous”
Does NOT develop motor fluctuations or dyskinesias with chronic levodopa use (unlike PD)
Response persists for decades without dose escalation
A levodopa trial is MANDATORY in ALL young-onset dystonia — failure to trial levodopa is a missed diagnosis of a treatable condition

Clinical Pearl

A child presenting with gait dystonia that worsens throughout the day and dramatically improves with low-dose levodopa = dopa-responsive dystonia (Segawa disease) until proven otherwise. The most common board error is failing to trial levodopa in young-onset dystonia.
DYT/PARK-TH (tyrosine hydroxylase deficiency) is the autosomal recessive form — more severe, may include encephalopathy, and shows only partial levodopa response.

Focal Dystonias

Focal dystonias are the most common form of dystonia in adults. Onset is typically in the 4th–6th decade. They remain confined to one body region and rarely generalize.

Type	Features	Key Points
Cervical dystonia (spasmodic torticollis)	Most common focal dystonia; involuntary head posturing; neck pain in ~75%	Torticollis (rotation), laterocollis (lateral tilt), retrocollis (extension), anterocollis (flexion); sensory trick common; head tremor in ~50%
Blepharospasm	Involuntary bilateral eyelid closure; second most common cranial dystonia	Bilateral; worsened by bright light, stress, driving; may cause functional blindness; distinguish from hemifacial spasm (unilateral, lower face involved)
Oromandibular dystonia	Involuntary jaw opening, closing, or lateral deviation	Jaw-closing type = masseters and temporalis; jaw-opening type = lateral pterygoids and digastrics; Meige syndrome = blepharospasm + oromandibular dystonia
Spasmodic dysphonia	Involuntary laryngeal muscle spasms affecting speech	Adductor type (most common): strained, strangled, breathy voice breaks; Abductor type: whispery, breathy voice; botulinum toxin to thyroarytenoid (adductor) or posterior cricoarytenoid (abductor)
Writer’s cramp	Task-specific dystonia of the hand during writing	Most common task-specific dystonia; “simple” (only during writing) vs. “dystonic” (extends to other manual tasks); musician’s dystonia is analogous

Sensory Trick (Geste Antagoniste)

Light touch to the chin, face, or back of head alleviates cervical dystonia in ~70% of patients
Highly specific for dystonia — rarely seen in other movement disorders
Mechanism: likely modulation of abnormal sensorimotor integration at the basal ganglia level
Diminishes over time in many patients

💎 Board Pearl

Cervical dystonia is the most common focal dystonia in adults. Botulinum toxin injection is first-line. Target muscles depend on the direction of pull: sternocleidomastoid for torticollis (contralateral), splenius capitis for torticollis (ipsilateral), and trapezius for laterocollis.
Meige syndrome = blepharospasm + oromandibular dystonia. It is a segmental cranial dystonia, not a focal dystonia.

Treatment

Botulinum Toxin (Focal Dystonia — First-Line)

Mechanism: cleaves SNARE proteins (synaptobrevin/SNAP-25) → blocks presynaptic acetylcholine release at the neuromuscular junction
Type A: onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin) — cleaves SNAP-25
Type B: rimabotulinumtoxinB (Myobloc) — cleaves synaptobrevin/VAMP; used when resistance develops to type A
Onset: 2–5 days; peak effect ~2 weeks; duration 3–4 months; requires repeat injections
Side effects: local weakness, dysphagia (cervical injections), ptosis (blepharospasm injections)
Antibody formation: develops in ~5%; results in secondary non-response; lower with Xeomin (complexing-protein-free); switch to type B
EMG or ultrasound guidance improves targeting accuracy for deep or small muscles

Oral Medications

Drug	Mechanism	Best For	Key Side Effects
Trihexyphenidyl	Anticholinergic (muscarinic antagonist)	Generalized dystonia, especially children	Dry mouth, blurred vision, urinary retention, cognitive impairment; children tolerate better than adults; titrate slowly to high doses (up to 60–100 mg/day in children)
Baclofen	GABA-B agonist	Adjunct for generalized/segmental	Sedation, weakness; withdrawal seizures if stopped abruptly; intrathecal baclofen pump for severe lower-limb dystonia
Clonazepam	GABA-A potentiator (benzodiazepine)	Adjunct; myoclonus-dystonia	Sedation, tolerance, dependence
Levodopa	Dopamine precursor	Dopa-responsive dystonia	Must trial in ALL young-onset dystonia; low-dose sufficient for DRD; not effective in most other dystonias
Tetrabenazine	VMAT2 inhibitor	Tardive dystonia	Depression, parkinsonism; may help some hyperkinetic dystonias

Deep Brain Stimulation (DBS)

Target: globus pallidus internus (GPi) — standard target for dystonia
Best outcomes: DYT-TOR1A generalized dystonia (>50% improvement in most); DYT-KMT2B also responds well
Response is gradual (weeks to months) unlike PD DBS (immediate tremor suppression)
Beneficial for medically refractory generalized, segmental, and cervical dystonia
Less effective for secondary/acquired dystonias (structural lesions, CP) — though some benefit possible
Subthalamic nucleus (STN) DBS is an emerging alternative target

Treatment Algorithm Summary

Step 1: Trial levodopa in ALL young-onset dystonia (rule out DRD)
Step 2 — Focal: Botulinum toxin (first-line)
Step 2 — Generalized: Trihexyphenidyl (first-line, especially in children); add baclofen or clonazepam as needed
Step 3: GPi DBS for medically refractory cases (generalized > segmental > cervical)

💎 Board Pearl

Botulinum toxin is first-line for all focal dystonias. It does NOT cure dystonia — repeat injections every 3–4 months are required.
GPi DBS for DYT-TOR1A: best surgical outcome among all dystonias; improvement is gradual over months (unlike PD DBS where tremor suppression is immediate).
Trihexyphenidyl in children: tolerated at much higher doses than adults; most effective oral medication for generalized dystonia.

Secondary Dystonias

Tardive Dystonia

Caused by chronic dopamine receptor blocker exposure (antipsychotics, metoclopramide)
More disabling than tardive dyskinesia; retrocollis and trunk extension (opisthotonus) are characteristic
May occur in isolation or combined with tardive dyskinesia
Treatment: stop/reduce offending agent; VMAT2 inhibitors (valbenazine, deutetrabenazine); botulinum toxin for focal components; trihexyphenidyl may help (unlike in tardive dyskinesia)
May persist indefinitely even after offending agent is discontinued

Wilson Disease

Always consider in any patient <50 years with unexplained dystonia
Autosomal recessive; ATP7B gene; copper accumulation in liver and brain (especially basal ganglia)
Dystonia is the most common movement disorder in neurological Wilson disease; may also cause tremor (“wing-beating”), parkinsonism, chorea
Kayser-Fleischer rings: slit-lamp examination; present in ~95% with neurologic involvement
Workup: low ceruloplasmin, elevated 24-hour urine copper, liver function tests, brain MRI (“face of the giant panda” sign in midbrain)
Treatment: D-penicillamine or trientine (copper chelation); zinc (blocks intestinal absorption); liver transplant for fulminant hepatic failure

Other Acquired Causes

Post-stroke dystonia: delayed onset (weeks to months); contralateral hemidystonia; basal ganglia or thalamic lesions
Cerebral palsy: most common cause of secondary dystonia in children; basal ganglia injury from perinatal asphyxia; may have delayed onset
Structural lesions: tumors, AVM, abscess involving basal ganglia or thalamus → contralateral hemidystonia
Post-traumatic: head injury with basal ganglia contusion; delayed onset common
Autoimmune: anti-NMDA receptor encephalitis (orofacial dyskinesias/dystonia); anti-basal ganglia antibodies
Toxic/metabolic: manganese exposure, carbon monoxide poisoning, methanol → basal ganglia necrosis with dystonia

Clinical Pearl

Wilson disease is the most important treatable cause of secondary dystonia. Screen every patient under 50 with unexplained dystonia or other movement disorder. Missing this diagnosis is both a board failure and a clinical tragedy — untreated Wilson disease is fatal.
Tardive dystonia responds to anticholinergics (trihexyphenidyl), unlike tardive dyskinesia where anticholinergics can worsen symptoms. This is a frequently tested distinction.

Paroxysmal Dystonias

Type	Gene	Trigger	Duration	Treatment
Paroxysmal kinesigenic dyskinesia (PKD)	PRRT2 (AD)	Sudden movement	Seconds to minutes (<5 min)	Low-dose carbamazepine (excellent response)
Paroxysmal non-kinesigenic dyskinesia (PNKD)	MR-1/PNKD (AD)	Alcohol, caffeine, stress, fatigue	Minutes to hours	Clonazepam; avoid triggers; carbamazepine less effective
Paroxysmal exercise-induced dyskinesia (PED)	SLC2A1 (GLUT1 deficiency)	Prolonged exercise (10–15 min)	Minutes to hours	Ketogenic diet (bypasses glucose transporter defect)

PRRT2 mutations also cause benign familial infantile epilepsy and infantile convulsions with choreoathetosis (ICCA syndrome)
SLC2A1 (GLUT1 deficiency): low CSF glucose (CSF:serum glucose ratio <0.4); also causes epilepsy, intellectual disability, acquired microcephaly

💎 Board Pearl

PKD + low-dose carbamazepine = near-complete resolution — this combination is highly board-testable. PRRT2 is the gene to remember.
PED + ketogenic diet: exercise-induced dystonia with low CSF glucose → think GLUT1 deficiency (SLC2A1). Ketogenic diet provides ketone bodies as alternative brain fuel.

References

Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863-873.
Balint B, Mencacci NE, Valente EM, et al. Dystonia. Nat Rev Dis Primers. 2018;4(1):25.
Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet. 1997;17(1):40-48.
Segawa M, Hosaka A, Miyagawa F, et al. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol. 1976;14:215-233.
Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86(19):1818-1826.
Volkmann J, Mueller J, Deuschl G, et al. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol. 2014;13(9):875-884.
Kupsch A, Benecke R, Müller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med. 2006;355(19):1978-1990.
Jinnah HA, Factor SA. Diagnosis and treatment of dystonia. Neurol Clin. 2015;33(1):77-100.